# Chemoradiotherapy With or Without Sintilimab in Limited-stage SCLC

> **NCT04189094** · PHASE2 · UNKNOWN · sponsor: **Zhejiang Cancer Hospital** · enrollment: 140 (estimated)

## Conditions studied

- Small Cell Lung Cancer Limited Stage

## Interventions

- **DRUG:** Sintilimab
- **DRUG:** Etoposide
- **DRUG:** Cisplatin
- **RADIATION:** radiotherapy

## Key facts

- **NCT ID:** NCT04189094
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-01
- **Primary completion:** 2021-07-01
- **Final completion:** 2023-07-01
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2019-12-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04189094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04189094, "Chemoradiotherapy With or Without Sintilimab in Limited-stage SCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04189094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*